Anti-angiogenesis Cancer Cure Strategies Catching on Slowly in the U.S

Since the mid-1980s, two "new" cancer fighting strategies have been much discussed, yet rarely utilized in the United States, anti-cancer vaccines and a class of drugs known as anti-angiogenesis or angiotensive drugs.  I first became aware of this problem, when, as a medical transcriptionist, I was devastated when one of my favorite doctors was diagnosed with a rare type of spinal cancer in the late 1980s.  A loyal member of the AMA, he utilized only AMA approved protocols, surgery, radiation and chemotherapy in a vain fight against the disease.  I was told that he had been planning to fly to Germany to try some of the treatments that had already been approved there when he died.

A few years later my now ex-wife and I did transcription through a contractor for a cutting edge cancer treatment center in California.  While we were doing transcription for them I learned of two then "experimental" protocols, that were being tried at that center but that had not yet received FDA approvals.  The first was the production of anti-cancer vaccines, which used the specific DNA of the patient's cancer to produce a vaccine that would allow the body's immune system to recognize the cancer as an invader and attack it directly.  After amazing success stories at the center, I heard very little about it's subsequent use.